NEW YORK, July 24, 2018 /PRNewswire/ --
If you want a free Stock Review on ALKS, ALNY, ALT, and ALXN sign up now at https://stocktraderreport.com/registration/. On Monday, July 23, 2018, the NASDAQ Composite closed the trading session at 7,841.87, up 0.28%; the Dow Jones Industrial Average edged 0.06% lower, to finish at 25,044.29; and the S&P 500 closed at 2,806.98, slightly advancing 0.18%. This Tuesday, StockTraderReport.com has released technical reports on the following Biotechnology stocks: Alkermes PLC (NASDAQ: ALKS), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), Altimmune Inc. (NASDAQ: ALT), and Alexion Pharmaceuticals Inc. (NASDAQ: ALXN). All you have to do is sign up today for this free limited time offer by clicking the link below. https://stocktraderreport.com/registration/
Ireland-based Alkermes PLC's stock finished Monday's session 0.09% lower at $45.00 with a total trading volume of 601,844 shares. The Company's shares have advanced 3.09% in the last month. The stock is trading below its 50-day moving average by 1.52%. Additionally, shares of Alkermes, which researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the US, Ireland, and internationally, have a Relative Strength Index (RSI) of 53.72.
On July 19th, 2018, Alkermes announced that it will host a conference call and webcast presentation at 8:30 a.m. ET on July 26th, 2018, to discuss the Company's Q2 2018 financial results. Management will also provide an update on the Company. The webcast player and accompanying slides may be accessed under the Investors section of the Company's website. Get the full research report on ALKS for free by clicking below at: https://stocktraderreport.com/registration/?symbol=ALKS
On Monday, shares in USA-headquartered Alnylam Pharmaceuticals Inc. recorded a trading volume of 479,719 shares. The stock ended the session 0.21% lower at $105.71. The Company's shares have advanced 10.28% in the previous three months and 28.88% over the last twelve months. The stock is trading above its 50-day moving average by 3.72%. Moreover, shares of Alnylam Pharma, which discovers, develops, and commercializes novel therapeutics based on RNA interference, have an RSI of 57.28.
On July 04th, 2018, Alnylam Pharma announced that the pivotal study results from the APOLLO Phase-3 trial of patisiran were published online that day in The New England Journal of Medicine. The study showed that patisiran improved measures of polyneuropathy, quality of life, activities of daily living, ambulation, nutritional status, and autonomic symptoms relative to placebo in patients with hereditary transthyretin-mediated amyloidosis, an inevitably progressive and generally fatal disease. Get access to our top-rated research, including the free report on ALNY at: https://stocktraderreport.com/registration/?symbol=ALNY
USA-headquartered Altimmune Inc.'s shares closed the day 1.25% lower at $0.40. The stock recorded a trading volume of 519,310 shares. The stock is trading below its 50-day moving average by 23.12%. Additionally, shares of Altimmune, which focuses on discovering and developing immunotherapies and vaccines to address the unmet medical needs, have an RSI of 42.00.
On July 10th, 2018, Altimmune announced that it has appointed Mitchel Sayare, Ph.D., as Executive Chairman of the Board, effective immediately. Dr. Sayare originally joined PharmAthene's Board of Directors in April 2010. Relevant to these efforts, Altimmune announced the hiring of José Ochoa as its Chief Business Officer. Mr. Ochoa joined Altimmune from IDT Biologika Corporation, where he served as Chief Business Officer & Head of Animal Health Americas. Click here to subscribe for a free membership which welcomes you with our report on ALT at: https://stocktraderreport.com/registration/?symbol=ALT
Shares in USA-based Alexion Pharmaceuticals Inc. finished 0.43% lower at $134.58. The stock recorded a trading volume of 1.19 million shares. The Company's shares have advanced 24.81% in the previous three months and 12.53% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 8.90% and 12.09%, respectively. Furthermore, shares of Alexion Pharma, which develops and commercializes various therapeutic products, have an RSI of 65.43.
On June 28th, 2018, Alexion Pharma announced that it will report its financial results for Q2 ended June 30th, 2018 before the US financial markets open on July 26th, 2018. Following the release of the financial results, management will conduct a conference call and audio webcast at 8:00 a.m. ET. The audio webcast can be accessed under the Investor page of the Company's website. To get free access to your research report on ALXN, sign up at: https://stocktraderreport.com/registration/?symbol=ALXN
Stock Trader Report:
Stock Trader Report (STR) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. STR has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
STR has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by STR. STR is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
STR, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. STR, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, STR, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither STR nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://stocktraderreport.com/privacy-policy/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 917-979-2038
Office Address: 22/F. 3 Lockhart Road, Wanchai Hong Kong
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Stock Trader Report